Arctic Bioscience – Q4 2022 Operational update – Key pharma milestones achieved and significant growth in revenues
Highlights Q4 2022: · Positive development for psoriasis drug candidate HRO350 according to plan, with approval of the Clinical Trial Application in the UK in January 2023 and first patient included in the UK · Total sales revenues more than doubled in Q4 2022 (NOK 10,6 million) compared to Q4 2021 (NOK 4,8 million) · First delivery of nutraceutical products to the Japanese market in Q4 2022 · Total sales revenue growth of 60 % in 2022, NOK 34,3 million in 2022 compared to NOK 21,5 million in 2021 · Strong development in gross margin in 2022, 34 % in 2022 compared to 24 % in